Bactorinol® Nasal Spray With Reduced-Dose Mometasone in Adults With Chronic Rhinosinusitis

Bactorinol® nasal spray is a medical device based on winterized Pistacia lentiscus oil,indicated as a support in cases of nasal congestion, to promote the fluidification ofsecretions and soothe irritated nasal mucosa. Pistacia lentiscus derivatives have beendescribed as having potential antimicrobial, antioxidant, and anti‐inflammatoryproperties.The study will evaluate whether the use of Bactorinol® nasal spray, included in a topicaltherapeutic strategy with intranasal corticosteroid, can improve quality of life andsymptoms in patients with chronic rhinosinusitis. The study population includes patientsdiagnosed with chronic rhinosinusitis with nasal polyposis and without nasal polyposis.This is a prospective, single‐center, randomized, controlled study with a 1:1 allocationratio. Participants will undergo a continuous 12‐week treatment period. The treated groupwill receive mometasone furoate nasal spray 1 puff daily plus Bactorinol® nasal spray 3puffs per nostril twice daily. The control group will receive mometasone furoate nasalspray 2 puffs daily.Participants will be monitored throughout the study for safety, adherence, and clinicaloutcomes. Clinical evaluations and monitoring of adverse events will be performed at thebeginning of the study and after 12 weeks of treatment.